Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease

Remo Panaccione, A. Hillary Steinhart, Brian Bressler, Reena Khanna, John K. Marshall, Laura Targownik, Waqqas Afif, Alain Bitton, Mark Borgaonkar, Usha Chauhan, Brendan Halloran, Jennifer Jones, Erin Kennedy, Grigorios I. Leontiadis, Edward Vincent Loftus, Jr, Jonathan Meddings, Paul Moayyedi, Sanjay Murthy, Sophie Plamondon, Greg RosenfeldDavid Schwartz, Cynthia H. Seow, Chadwick Williams, Charles N. Bernstein

Research output: Contribution to journalArticle

Abstract

Background & Aims: Crohn's disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods: We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results: The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions: Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.

Original languageEnglish (US)
JournalClinical Gastroenterology and Hepatology
DOIs
StatePublished - Jan 1 2019

Fingerprint

Practice Management
Practice Guidelines
Crohn Disease
Therapeutics
Immunosuppressive Agents
Mesalamine
Adrenal Cortex Hormones
Biological Factors
Anti-Bacterial Agents
Budesonide
Biological Therapy
Patient Preference
Methotrexate

Keywords

  • 5-ASA
  • Guidance
  • Mucosal Healing
  • TNF

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. / Panaccione, Remo; Steinhart, A. Hillary; Bressler, Brian; Khanna, Reena; Marshall, John K.; Targownik, Laura; Afif, Waqqas; Bitton, Alain; Borgaonkar, Mark; Chauhan, Usha; Halloran, Brendan; Jones, Jennifer; Kennedy, Erin; Leontiadis, Grigorios I.; Loftus, Jr, Edward Vincent; Meddings, Jonathan; Moayyedi, Paul; Murthy, Sanjay; Plamondon, Sophie; Rosenfeld, Greg; Schwartz, David; Seow, Cynthia H.; Williams, Chadwick; Bernstein, Charles N.

In: Clinical Gastroenterology and Hepatology, 01.01.2019.

Research output: Contribution to journalArticle

Panaccione, R, Steinhart, AH, Bressler, B, Khanna, R, Marshall, JK, Targownik, L, Afif, W, Bitton, A, Borgaonkar, M, Chauhan, U, Halloran, B, Jones, J, Kennedy, E, Leontiadis, GI, Loftus, Jr, EV, Meddings, J, Moayyedi, P, Murthy, S, Plamondon, S, Rosenfeld, G, Schwartz, D, Seow, CH, Williams, C & Bernstein, CN 2019, 'Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease', Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2019.02.043
Panaccione, Remo ; Steinhart, A. Hillary ; Bressler, Brian ; Khanna, Reena ; Marshall, John K. ; Targownik, Laura ; Afif, Waqqas ; Bitton, Alain ; Borgaonkar, Mark ; Chauhan, Usha ; Halloran, Brendan ; Jones, Jennifer ; Kennedy, Erin ; Leontiadis, Grigorios I. ; Loftus, Jr, Edward Vincent ; Meddings, Jonathan ; Moayyedi, Paul ; Murthy, Sanjay ; Plamondon, Sophie ; Rosenfeld, Greg ; Schwartz, David ; Seow, Cynthia H. ; Williams, Chadwick ; Bernstein, Charles N. / Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. In: Clinical Gastroenterology and Hepatology. 2019.
@article{c880681ce5044140a9bfc70648ad6ee2,
title = "Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease",
abstract = "Background & Aims: Crohn's disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods: We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results: The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions: Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.",
keywords = "5-ASA, Guidance, Mucosal Healing, TNF",
author = "Remo Panaccione and Steinhart, {A. Hillary} and Brian Bressler and Reena Khanna and Marshall, {John K.} and Laura Targownik and Waqqas Afif and Alain Bitton and Mark Borgaonkar and Usha Chauhan and Brendan Halloran and Jennifer Jones and Erin Kennedy and Leontiadis, {Grigorios I.} and {Loftus, Jr}, {Edward Vincent} and Jonathan Meddings and Paul Moayyedi and Sanjay Murthy and Sophie Plamondon and Greg Rosenfeld and David Schwartz and Seow, {Cynthia H.} and Chadwick Williams and Bernstein, {Charles N.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.cgh.2019.02.043",
language = "English (US)",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease

AU - Panaccione, Remo

AU - Steinhart, A. Hillary

AU - Bressler, Brian

AU - Khanna, Reena

AU - Marshall, John K.

AU - Targownik, Laura

AU - Afif, Waqqas

AU - Bitton, Alain

AU - Borgaonkar, Mark

AU - Chauhan, Usha

AU - Halloran, Brendan

AU - Jones, Jennifer

AU - Kennedy, Erin

AU - Leontiadis, Grigorios I.

AU - Loftus, Jr, Edward Vincent

AU - Meddings, Jonathan

AU - Moayyedi, Paul

AU - Murthy, Sanjay

AU - Plamondon, Sophie

AU - Rosenfeld, Greg

AU - Schwartz, David

AU - Seow, Cynthia H.

AU - Williams, Chadwick

AU - Bernstein, Charles N.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background & Aims: Crohn's disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods: We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results: The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions: Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.

AB - Background & Aims: Crohn's disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods: We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results: The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions: Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.

KW - 5-ASA

KW - Guidance

KW - Mucosal Healing

KW - TNF

UR - http://www.scopus.com/inward/record.url?scp=85064715594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064715594&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2019.02.043

DO - 10.1016/j.cgh.2019.02.043

M3 - Article

C2 - 30853616

AN - SCOPUS:85064715594

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

ER -